Dementia Congress Market Analysis and Reports | Japan Conference Series

Market Analysis - Dementia Congress 2019

Why in Japan?

With one in five elderly Japanese predicted to have dementia by 2025, entire communities are working to improve the lives of older citizens and more 4.6 million people are living with dementia. And this number is expected to rise significantly as the population ages. Worldwide, at least 44 million people are living with dementia.

Importance and Scope:

The global market for treatments for syndromes of dementia and movement disorders was valued at 10.5 billion in 2011 and should reach $11.1 billion in 2012. Total market value is expected to reach $16.7 billion in 2017 after increasing at a five-year compound annual growth rate (CAGR) of 8.5%.

Someone in the world develops dementia every 3 seconds. There were an estimated 46.8 million people worldwide living with dementia in 2015 and this number is believed to be close to 50 million people in 2017. This numbers will almost double every 20 years, reaching 75 million in 2030 and 131.5 million in 2050. Much of the increase will be in developing countries. Already 58% of people with dementia live in low and middle income countries, but by 2050 this will rise to 68%. The fastest growth in the elderly population is taking place in China, India, and their south Asian and western Pacific neighbours.

Major Neuroscience Societies and Associations in Tokyo:

World Federation of Neurology

Japanese Society of Child Neurology

Neurospinal Society of Japan

Cognitive Neuroscience Group

 

Major Dementia and Alzheimer’s Societies and Associations around Globe:

Alzheimer's Australia

Hilarescere Foundation in Italy

Alzheimer Society of Bangladesh

Alzheimer Support Group

Alzheimer's Association

Southern Clinical Neurological Society

American Academy of Neurology

ESNR European Society of Neuroradiology

European Neurological Societies

Alzheimer Austria

Foundation Alzheimer Aruba (FAA)

Alzheimer's disease Chinese

Spanish Society of Neurology

Alzheimer's Society

Major Neurological Associations in Italy

British brain tumor association

 

Top Neuroscience Universities in Japan

Aino University

Osaka Kawasaki Rehabilitation University

Hagoromo International University

Osaka University of Human Sciences

Hannan University

Soai University

Heian Jogakuin-St. Agnes'-University

Tokiwakai Gakuen University

Kansai Medical University

Osaka University

Kinki University

Okinawa Institute of Science and Technology

Kwansei Gakuin University, Osaka-Umeda

Keio University

Morinomiya University of Medical Sciences

Nagoya University


Top Neuroscience Universities in Globe:

Dalhousie University

University of Nottingham

Leiden University

Cardiff University

Temple University USA

University of Toronto

University Oklahoma

University Sheffield

University of Bristol

University California

Florida International University

University of Amsterdam

University of Edinburgh

Karolinska Institute

University of Milan

University of Gothenburg


Hospital Associated with Neuroscience:

Osaka University Hospital

Tokyo metropolitan neurological hospital

Kosei Nenkin Hospital

Shonan kamakura general hospital

Sumitomo Hospital

Jikei university school of medicine hospital

Yodogawa Christian Hospital

Yamaguchi university hospital

Wada Hospital

The university of tokyo hospital

Ueda Surgery Hospital

St. luke's international hospital

Osaka University Hospital

Japan bangladesh friendship hospital

Kosei Nenkin Hospital

Tokyo metropolitan neurological hospital

 

Companies Associated with Neuroscience in Japan

Pfizer

Forest Laboratories

GlaxoSmithKline

Eli Lilly

Solvay of Belgium

Wyeth Pharmaceuticals

Fujisawa Pharmaceutical

Organon International

Meiji Seika

Lund beck

Janssen Pharmaceutical

Asahi Kasei Corporation


Top Neuroscience Companies:

Brainomix

Polyneuron Pharmaceuticals AG Corp.

reHaptix GmbH

Biogen Idec

KB Medical

Intento SA

OncoVision

AcelRx Pharmaceuticals, Inc.

Trevena

AcelRx Pharmaceuticals, Inc.

Mintlabs

Mylan

Actavis

Bayer

Lundbeck

Novartis

Glance at market of dementia:-

There were an expected 46.8 million individuals overall living with dementia in 2015 and this number is accepted to be near 50 million individuals in 2017. This number will twofold at regular intervals, achieving 75 million out of 2030 and 131.5 million out of 2050. A great part of the expansion will be in creating nations. Officially 58% of individuals with dementia live in low and center pay nations, yet by 2050 this will ascend to 68%. The quickest development in the elderly populace is occurring in China, India, and their south Asian and western Pacific neighbors. The evaluated for the aggregate number of dementia sufferers worldwide in the years 2015, 2030 and 2050. It is evaluated that there will be around 75 million individuals experiencing dementia in 2030.

Statistic maturing is an overall procedure that demonstrates the achievements of enhanced human services in the course of the most recent century. Many are presently living longer and more beneficial lives thus the total populace has a more noteworthy extent of more seasoned individuals. Dementia principally influences more seasoned individuals, in spite of the fact that there is a developing familiarity with cases that begin before the age of 65. There are more than 9.9 million new instances of dementia every year around the world, inferring one new case at regular intervals.

The World Alzheimer Report 2015 updates ADI's worldwide assessments of the predominance, occurrence and expenses of dementia in view of efficient surveys. The report makes key suggestions to give a worldwide structure to activity on dementia. The report likewise incorporates a survey of the proof for and against late patterns in the predominance and frequency of dementia after some time, and in addition an examination of the more extensive societal effect of dementia. The aggregate assessed overall expense of dementia is US$818 billion of every 2015, which speaks to 1.09% of worldwide GDP. By 2018, the worldwide expense of dementia will transcend a US$ trillion.

Coordinate therapeutic consideration costs represent around 20% of worldwide dementia costs, while coordinate social area costs and casual consideration costs each record for about 40%. The relative commitment of casual consideration is most prominent in the African areas and least in North America, Western Europe and some South American districts, while the turnaround is valid for social part costs.  This implies if worldwide dementia care were a nation, it would be the eighteenth biggest economy on the planet.

 

Some products manufactured by the industry related Neuroscience Research:-

  •  NeuroScience ImmuWell.
  • NeuroScience AdreCor.
  • NeuroScience Calm CP.
  • Kavinace .
  • Purified anti-β-Dystroglycan Antibody.
  • Alexa Fluor® 594 anti-Neurofilament H (NF-H), Phosphorylated Antibody.
  • Mouse & Rat Spinal Cord Matrices.
  • Surgical & Dissection Tools. 

 Target Audience:

Neurologists and Directors, Physicians, Neuroscientists, Specialists, researchers, health care professionals, Professors, Lecturers and Students from Academia in the study of Dementia.

Products manufactured by the industries:

Three drugs are available to treat symptoms in people with Mild to moderate Alzheimer’s disease

Aricept™ produced by Pfizer Canada Inc.,

Exelon™ produced by Novartis Pharma Canada Inc.

Reminyl™ produced by Janssen Ortho Inc.

Two drugs for Moderate to advanced Alzheimer’s disease

Ebixa®

Aricept™

Dementia congress 2019 welcomes attendees, presenters, and exhibitors from all over the world to Singapore. We are delighted to invite you all to attend and register for the“13th World Congress on Advances and Innovations in Dementia” which is going to be held during May 22-23, 2019 Tokyo, Japan.

The organizing committee is gearing up for an exciting and informative conference program including plenary lectures, symposia, workshops on a variety of topics, poster presentations and various programs for participants from all over the world. We invite you to join us at the Dementia congress 2019, where you will be sure to have a meaningful experience with scholars from around the world. All members of the Dementia congress 2019 organizing committee look forward to meeting you in Tokyo, Japan.

For more details please visit - http://dementiacongress.neurologyconference.com